Bleeding out: Theranos oozes with corporate governance lessons
A year ago, Theranos was a Silicon Valley health tech “unicorn” praised for breakthrough advancements in blood testing. Now it’s under civil and criminal investigation for defrauding investors. The role Theranos’ board has played in this is already shaping up to be a pointed object lesson for board best practices ...
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
LendingClub could teach Theranos a thing or two about crisis management
Relatively young, technology-based companies face special difficulties when dealing with crises. Their focus on market disruption and their lack of established credibility make earning public trust even more difficult. And yet, LendingClub shows how it can be done at a time when Theranos certainly failed the crisis management test. David ...
-
PremiumShould Tesla board, compliance rein in Musk? Expert says tech tycoon ‘doubly untouchable’
Tesla’s chief executive Elon Musk has admitted he’s leading his businesses “with great difficulty” while serving as President Trump’s senior adviser. The carmaker’s shareholders are openly questioning his bandwidth. Why isn’t Tesla’s board firing him? He’s “doubly untouchable,” a corporate governance expert says.
-
PremiumShareholders back Apple sticking to DEI goals as Trump blasts move
Tech giant Apple solidified its commitment to diversity, equity, and inclusion at its annual shareholder meeting on Tuesday, with 97 percent of shareholders rejecting an anti-DEI proposal, according to a public filing.